Cisco (CSCO) dips on seventh straight quarterly sales decline >>> READ MORE

4 Pharmaceutical Stocks to Sell Now

DRRX, DEPO, CADX, CORT slump in weekly rankings


The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”)

Durect (NASDAQ:DRRX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Durect is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. DRRX also rates an F in Portfolio Grader’s specific subcategory of Sales Growth. For a full analysis of DRRX stock, visit Portfolio Grader

Depomed‘s (NASDAQ:DEPO) rating falls this week to a F (“strong sell”), down from last week’s D (“sell”). Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. The stock rates an F in Earnings Momentum, Earnings Revisions, and Equity. Cash Flow, Margin Growth, and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of DEPO stock

The rating of Cadence Pharmaceuticals (NASDAQ:CADX) declines this week from a D to a F Cadence Pharmaceuticals focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. The stock gets F’s in Equity and Cash Flow. The stock price has dropped 1% over the past month, worse than the 3.3% increase the Nasdaq has seen over the same period of time. To get an in-depth look at CADX, get Portfolio Grader’s complete analysis of CADX stock

This week, Corcept Therapeutics‘s (NASDAQ:CORT) rating worsens to a D from the company’s C rating a week ago. Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow Wall Street appears to agree with the stock downgrade, with share prices dropping 17.3% over the past month For more information, get Portfolio Grader’s complete analysis of CORT stock

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC